Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 5,052.20 |
| Open | 5,048.75 |
| Bid | 5,036.90 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 4,985.00 - 5,105.35 |
| 52 Week Range | 2,495.05 - 5,512.65 |
| Volume | 762,986 |
| Avg. Volume | 1,317,009 |
| Market Cap | 835.773B |
| Beta (5Y Monthly) | 0.00 |
| PE Ratio (TTM) | 54.49 |
| EPS (TTM) | 92.43 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | 25.00 (0.49%) |
| Ex-Dividend Date | Jul 13, 2020 |
| 1y Target Est | 2,587.45 |
- Zacks
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
- Business Wire
Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
- Business Wire
Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.
© 2021 Verizon Media. All rights reserved.
